ExploreWatchlistsPricing
  1. JP-listed companies
  2. JCR Pharmaceuticals Co.,Ltd.
  3. Financials
  4. Income before tax

JCR Pharmaceuticals Co.,Ltd. (4552)

Market cap
¥73.8B
P/E ratio
43.4x
JCR Pharma develops and manufactures pharmaceutical and regenerative medicine products for healthcare providers worldwide, with specialized focus on advanced regenerative treatments.
SummaryFinancialsDividendsHistorySegmentsOwnershipWorkforce
Period EndIncome before tax (Million JPY)YoY (%)
Mar 31, 2025-7,477-202.93%
Mar 31, 20247,264+34.07%
Mar 31, 20235,418-73.59%
Mar 31, 202220,512+141.66%
Mar 31, 20218,488+157.76%
Mar 31, 20203,293-35.02%
Mar 31, 20195,068+31.88%
Mar 31, 20183,843+51.64%
Mar 31, 20172,534+3.74%
Mar 31, 20162,443+4.39%
Mar 31, 20152,340+39.23%
Mar 31, 20141,681+45.37%
Mar 31, 20131,156+15.00%
Mar 31, 20121,005

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat